Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study

Hess, Georg ; Dreyling, Martin ; Oberic, Lucie ; Gine, Eva ; Zinzani, Pier Luigi ; Linton, Kim ; Vilmar, Adam ; Jerkeman, Mats LU ; Chen, Jenny M.H. and Ohler, Anke , et al. (2023) In British Journal of Haematology 202(4). p.749-759
Abstract

Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi-based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6–20.0) in the overall... (More)

Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi-based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6–20.0) in the overall cohort, 5.5 months (95% CI 3.9–8.2) in 91 patients without post-BTKi therapy, and 23.8 months (95% CI 18.9–30.1) in 149 patients who received post-BTKi therapy (excluding chimeric antigen receptor T-cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post-BTKi therapy, with lenalidomide-containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post-BTKi therapy was 9.7 months (95% CI 6.3–12.7). These results provide a benchmark for survival in patients with R/R MCL receiving salvage therapy after BTKi failure.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Bruton tyrosine kinase inhibitor, mantle cell lymphoma, post-BTKi, real-world evidence, survival
in
British Journal of Haematology
volume
202
issue
4
pages
749 - 759
publisher
Wiley-Blackwell
external identifiers
  • pmid:36257914
  • scopus:85140099104
ISSN
0007-1048
DOI
10.1111/bjh.18519
language
English
LU publication?
yes
id
b0e44972-9f0e-46af-838b-9e62451ebd08
date added to LUP
2023-01-16 15:04:36
date last changed
2024-04-17 20:39:01
@article{b0e44972-9f0e-46af-838b-9e62451ebd08,
  abstract     = {{<p>Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments is limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR-2, addresses this knowledge gap and reports on data collected from 240 patients with relapsed/refractory MCL in Europe who were treated with BTKi-based therapy between July 2012 and July 2018, and had experienced disease progression while on BTKi therapy or discontinued BTKi therapy due to intolerance. The median overall survival (OS) from initiation of first BTKi therapy was 14.6 months (95% confidence interval [CI] 11.6–20.0) in the overall cohort, 5.5 months (95% CI 3.9–8.2) in 91 patients without post-BTKi therapy, and 23.8 months (95% CI 18.9–30.1) in 149 patients who received post-BTKi therapy (excluding chimeric antigen receptor T-cell treatment). In the latter group, patients received a median of one (range, one to seven) line of post-BTKi therapy, with lenalidomide-containing regimens and bendamustine plus rituximab being the most frequently administered; the median OS from initiation of first post-BTKi therapy was 9.7 months (95% CI 6.3–12.7). These results provide a benchmark for survival in patients with R/R MCL receiving salvage therapy after BTKi failure.</p>}},
  author       = {{Hess, Georg and Dreyling, Martin and Oberic, Lucie and Gine, Eva and Zinzani, Pier Luigi and Linton, Kim and Vilmar, Adam and Jerkeman, Mats and Chen, Jenny M.H. and Ohler, Anke and Stilgenbauer, Stephan and Thieblemont, Catherine and Lambert, Jonathan and Zilioli, Vittorio Ruggero and Sancho, Juan Manuel and Ubieto, Ana Jimenez and Fischer, Luca and Eyre, Toby A. and Keeping, Sam and Park, Julie E. and Wu, James J. and Siddiqi, Rubina and Reitan, John and Wade, Sally and Salles, Gilles}},
  issn         = {{0007-1048}},
  keywords     = {{Bruton tyrosine kinase inhibitor; mantle cell lymphoma; post-BTKi; real-world evidence; survival}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{749--759}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{British Journal of Haematology}},
  title        = {{Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study}},
  url          = {{http://dx.doi.org/10.1111/bjh.18519}},
  doi          = {{10.1111/bjh.18519}},
  volume       = {{202}},
  year         = {{2023}},
}